|
|
Small
enough to fit into a life this full
Setting
High Standards in Growth Hormone Therapy
Precise
GH delivery helps maintain a normal routine
 | Prefilled, premeasured (single-dose) device helps ensure
accurate dosing
| Automatic internal mixing allows simple reconstitution
| Full amount of drug is delivered for less waste—maximizing
cost savings1 |
| |
1. Nahata M., Morosco R. Reconstitution and
utilization of growth hormone (somatropin) in three drug delivery
systems. J Pediatr Pharm Pract. 1998;3(3):166-169.
Portability
and flexibility for a full life
| Small size and room temperature storage* allow for easy
portability
| Packaged in a 7-day supply to simplify travel
| 10 dosage strengths (from 0.2 mg to 2.0 mg, in 0.2-mg
increments) for flexible dosing |
| |
No
refrigeration necessary*
*Genotropin
MiniQuick can be stored at room temperature for up to 3 months.
Easy-to-teach
GH delivery
| A. Attach the needle |
 |
| B. Twist |
 |
| C. Inject |
 |
Footnote:
Health care providers should supervise the first
injection and be able to answer patient questions on proper use of
reconstitution and delivery devices for GENOTROPIN. Patients and
parents should be instructed to visually inspect the solution for
particulate matter and discoloration prior to administration.
Indication
GENOTROPIN® Lyophilized Powder (somatropin [rDNA origin] for
injection) is indicated for the long-term treatment of children who
have growth failure due to an inadequate secretion of endogenous
growth hormone (GH). Other causes of short stature should be
excluded. GENOTROPIN is also indicated for long-term replacement
therapy in adults with growth hormone deficiency (GHD) of either
childhood- or adult-onset etiology. GHD should be confirmed by an
appropriate growth hormone stimulation test.
Special Considerations
Growth hormone should not be initiated to treat patients with acute
critical illness due to complications of surgery, trauma, or
respiratory failure; the safety of continuing treatment in patients
who develop acute critical illness during treatment with GH for
approved uses has not been established. Patients with diabetes
mellitus or glucose intolerance should be monitored closely, and
insulin dosage may need to be adjusted during treatment with GH.
Careful monitoring is also necessary if GH is administered in
combination with other drugs metabolized by the CP450 pathway. GH
should be used during pregnancy only if clearly needed and with
caution in nursing mothers.
Physicians should be aware of the following precautions:
Intracranial hypertension has been reported in a small number of
patients; a higher incidence of slipped capital femoral epiphyses (SCFE)
has been reported in pediatric patients with endocrine disorders. In
clinical trials with GENOTROPIN in adults with GHD, the majority of
side effects were symptoms of fluid retention, including peripheral
swelling/edema, arthralgia, pain and stiffness of the extremities,
myalgia, paresthesia, and hypoesthesia. These events were reported
early in therapy and tended to be transient/responsive to dosage
reduction.
|
|
|
